List of publications on a keyword: «синтетические каннабимиметики»


Publication date: 14.06.2019
Evaluate the material Average score: 0 (Всего: 0)
Andrey V. Antsyborov , graduate student
Mental Health Clinic «Psyche» , Ростовская обл
Irina V. Dubatova , candidate of medical sciences , associate professor
FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health , Ростовская обл

«New psychoactive substances: psychiatrist's view»

Download an article

Appearing not long ago, new psychoactive substances (designer drugs), including synthetic cannabinoids, derivatives of cathinone, phenethylamines, new stimulants, synthetic opioids, tryptamine derivatives, phencyclidine, piperazine, the GABA (A/B) receptors agonists, have become a serious problem for consumers and for physicians. Consumers of these substances are attracted primarily by the intensity of psychoactive effects, and the «legal high» declared by the black manufacturers, which indicates that significant difficulties in a laboratory identification of new surfactants. Designer drugs, when ingested, can be influenced on many neurotransmitter pathways/receptors: dopamine, cannabinoid (CB1), GABA (A/B), 5-HT2A, glutamate, and k-opioid receptors (KOR), the imbalance of which leads to the development of polymorphic psychotic disorders.